Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial
Ḱazunori Toyoda(National Cerebral and Cardiovascular Center), Naoko Kumagai(Tohoku University), Kortaro Tanaka(University of Toyama), Satoshi Yasuda(Tohoku University), Kiyohiro Houkin(Hokkaido University), Shinichiro Uchiyama(International University of Health and Welfare), Yasuo Terayama(Neurology, Inc), Nobuyuki Sakai(Shizuoka City Shimizu Hospital), Shinya Goto(Tokai University), J. Donald Easton(University of California, San Francisco), Masayasu Matsumoto, Kazuo Minematsu(Kishokai Medical Corporation), Keiji Yamaguchi, Kazumi Kimura(Nippon Medical School), Tatsuya Isomura, Haruhiko Hoshino(Saiseikai Central Hospital), Masanori Isobe(Kushiro Rosai Hospital), Yasushi Okada(National Kyushu Medical Center), Hiroaki Naritomi, Teiji Tominaga(Tohoku University), Hidekazu Tomimoto(Saiseikai Ibaraki Hospital), Takenori Yamaguchi(National Cerebral and Cardiovascular Center), Hideki Origasa(University of Toyama)
Cited by 216
Related Papers
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
|New England Journal of Medicine|2015|2k
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
|New England Journal of Medicine|2011|1.9k
Transient Ischemic Attack — Proposal for a New Definition
|New England Journal of Medicine|2002|842
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
|New England Journal of Medicine|2019|809